MARKET

BIO

BIO

Bio Rad Labs Inc
NYSE
290.86
-1.89
-0.65%
Pre Market: 286.50 -4.36 -1.50% 04:23 04/18 EDT
OPEN
297.04
PREV CLOSE
292.75
HIGH
299.22
LOW
290.40
VOLUME
95
TURNOVER
0
52 WEEK HIGH
494.05
52 WEEK LOW
261.59
MARKET CAP
8.29B
P/E (TTM)
-13.3303
1D
5D
1M
3M
1Y
5Y
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Bio-Rad Laboratories, Inc. Has US$1.19b in debt on its balance sheet. The company has more cash than debt, and has net cash of US$417.7m. Its debt levels are a concern, but the company has a healthy balance sheet for the long-term. Bio- Rad Laboratories's EBIT has tanked 25% in the last 12 months. The business needs free cash flow to pay off debt.
Simply Wall St · 6h ago
Commit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using Options
NASDAQ · 1d ago
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
NASDAQ · 2d ago
Weekly Report: what happened at BIO last week (0408-0412)?
Weekly Report · 3d ago
Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Bio-Rad is a "picks and shovels" company in the life sciences industry but lacks standout growth, margins, or returns. The company saw double-digit declines in its Life Sciences segment in the last two quarters. Bio-Rad's holdings in Sartorius bring significant value to the company, but it's hard to love the stock on its own.
Seeking Alpha · 4d ago
Oncocyte stock rallies 90% post-market on Bio-Rad partnership
Oncocyte announced a partnership with Bio-Rad for the global launch of its GraftAssure assay for organ transplant monitoring. The product is slated to be launched in Q2 to select academic transplant centers in the US and EU. Oncocyte stock rallies 90% post-market on Bio- Rad partnership.
Seeking Alpha · 6d ago
Oncocyte, Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte and Bio-Rad agree to a partnership agreement to commercialize the research use only GraftAssure assay. The product is expected to launch in the second quarter to a select group of academic transplant centers in the U.S. And EU. The companies will co-market the assay in the US and Germany. Oncocyte uses donor-derived cell-free DNA to assess organ health.
Dow Jones · 6d ago
BUZZ-OncoCyte jumps on partnership with Bio-Rad
OncoCyte shares rise 93.3% to $5.73 in extended trading. Company announces partnership with Bio-Rad for blood-based organ transplantation monitoring test GraftAssure. Shares of diagnostics company up 18.6% year-to-date.
Reuters · 6d ago
More
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Webull offers Bio Rad Laboratories Inc stock information, including NYSE: BIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIO stock methods without spending real money on the virtual paper trading platform.